BRIM Biotechnology strengthens leadership team in preparation for transformational year ahead
Taipei, Taiwan, February 20th, 2023 / Sciad Newswire / BRIM Biotechnology, Inc. (BRIM, TPEx 6885), a clinical-stage company developing novel
regenerative therapies to help combat and cure ophthalmology and
degenerative joint diseases, is pleased to announce that Andrew Lin was
elected as the new Chairman of the Board on 8th February,
2023, and that the new board has appointed Dr. Wen-Chyi Shyu as the
company’s new Chief Executive Officer (CEO) from 1st March, 2023. The new leadership team will guide BRIM through what is set to be a transformational year for the company.
More info >> |